CONTRAVE® is a prescription medicine. Please review the full Data Sheet before prescribing, available on the Medsafe website www.medsafe.govt.nz. CONTRAVE® 8/90 (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets). Indications: CONTRAVE is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obese) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). Treatment with CONTRAVE should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight. Dosage and Administration: Swallow tablets whole with water, and preferably with food. Dose should be escalated over a 4-week period from initiation. The recommended starting dose is 1 tablet in the morning for 1 week, increasing to 1 tablet in the morning and 1 at night in the second week, 2 tablets in the morning and 1 tablet at night in the third week. The maintenance dose from week 4 onward is 2 tablets in the morning and 2 at night. Contraindications: Hypersensitivity to bupropion, naltrexone or any of the excipients, uncontrolled hypertension, seizure disorder or a history of seizures, patients with a known central nervous system tumour, patients undergoing acute alcohol or benzodiazepine withdrawal, patients with a history of bipolar disorder, use of concomitant treatment containing bupropion or naltrexone, current or previous diagnosis of bulimia or anorexia nervosa, patients currently dependent on chronic opioids or opiate agonists, or patients in acute opiate withdrawal, pregnancy, patients with severe hepatic impairment, patients with end-stage renal failure, and in concomitant administration with monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with CONTRAVE. Starting CONTRAVE in a patient treated with reversible MAOIs is also contraindicated. Warnings and Precautions: Safety and tolerability should be assessed at regular intervals. Safety and efficacy of CONTRAVE for longer than a year has not been established. Suicidal ideation has been reported in post marketing reports with CONTRAVE and patients should be supervised closely. There is a small increase in the risk of seizure. In patients requiring intermittent opiate treatment, CONTRAVE should be temporarily discontinued and lower doses of opioids may be needed. A patient should stop taking CONTRAVE and consult a doctor if experiencing any allergic symptoms during treatment. Use with caution in those with controlled hypertension, predisposing factors that increase the likelihood of seizing, reduced renal clearance, underlying liver disease, history of mania and patients aged greater than 65. Caution in performing activities requiring mental alertness e.g. driving and operating machinery. Pregnancy and lactation: Category B2. Safe use of naltrexone/bupropion in combination has not been established with respect to adverse effects on foetal development. Adverse Effects: Decreased lymphocyte count, palpitations, tinnitus, vertigo, nausea, constipation, vomiting, dry mouth, toothache, upper abdominal pain, feeling jittery, dizziness, tremor, dysgeusia, disturbance in attention, lethargy, hot flush, hyperhidrosis, pruritus and alopecia. Interactions: Contraindicated in use with MAOIs, drugs containing bupropion, chronic opioid use or opiate agonist therapy. CONTRAVE may increase the availability of other medicines metabolised by CYP2D6 substrate. Medicines metabolised by the CYP2B6 isozyme may interact with CONTRAVE. Use with caution with drugs that lower the seizure threshold and dopaminergic drugs. Avoid or minimise the use of alcohol.

DUROMINE IS A C5 CONTROLLED DRUG. DUROMINE IS AN UNFUNDED MEDICINE – A PRESCRIPTION CHARGE WILL APPLY. PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING AVAILABLE AT WWW.MEDSAFE.GOVT.NZ OR PHONE Freephone 0508 375394. Minimum Data Sheet Information (phentermine). DUROMINE Indications: For the management of obesity as a short-term adjunct in a medically monitored weight loss programme based on exercise, diet and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m2 or greater. DUROMINE may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. Dosage and Administration: The usual starting dose in adults and children over 12 years is 30 mg once daily at breakfast. Continuous or inter-mittent maintenance dose is 15 mg to 30 mg once daily depending on responsiveness. Patients require medical review after a defined course of treatment, which should not exceed three months. Available in 15 mg and 30 mg capsules. Contraindications: Pulmonary artery hypertension, heart valve abnormalities, heart murmurs, moderate to severe hypertension, cerebrovascular disease, severe cardiac disease including arrhythmias, advanced arteriosclerosis, hypersensitivity to sympathomimetic drugs, hyperthyroidism, psychiatric illnesses, glaucoma, drug/alcohol abuse or dependence, concomitant MAOIs or within 14 days of MAOI use. Precautions: Short term monotherapy only. Co-administration of drug products for weight loss is not recommended. There have been no reported cases of valvular heart disease occurring with phentermine alone. Use with caution in mild hypertension, established coronary artery disease, epilepsy, and in those receiving insulin, oral hypoglycaemic agents or psychotropic agents. Adverse Effects: The most common are palpitations, tachycardia, elevation of blood pressure and precordial pain. Others included restlessness, insomnia, nausea, and dry mouth. Psychotic episodes, hallucinations and serious cardiovascular or cerebrovascular events are rare. Full Data Sheet and Consumer Medicine Information is available from Medsafe at www. medsafe.govt.nz.

Efudix, Prescription Medicine, is used to treat precancerous and cancerous growths, affecting the outer layer of skin, caused by ageing or exposure to sunlight including Keratoses, including senile, actinic and arsenical forms (known as sun spots), Bowen’s disease (type of skin cancer, Superficial Basal Cell Carcinoma (type of skin cancer) and Keratoacanthoma. Active ingredient Fluorouracil 5% w/w Cream. Efudix has risks and benefits. Please refer to the data sheet on www.medsafe.govt.nz

HIPREX is a General Sale Medicine for the suppression or elimination of urinary tract bacteria. Contains Hexamine hippurate 1g per tablet, available 20 and 100 tablet bottles. 100 tablet bottle is a fully funded medicine, a prescription charge will apply. Dose: adults 1 tablet twice daily, children 6-12 years ½ – 1 tablet twice daily. Do not give to children under 6 years. Contraindications: severe hepatic impairment; renal impairment; severe dehydration; metabolic acidosis; gout; acute parenchymal infections. Pregnancy: Category A. Interactions: alkalinising agents; sulphonamides. Adverse Effects: nausea, upset stomach, stomatitis, dysuria, rash.

NORFLEX is a prescription medicine. Please review the full Data Sheet before prescribing, available on the Medsafe website www.medsafe.govt.nz NORFLEX Tablets are fully funded on the Pharmaceutical Schedule. NORFLEX™: Orphenadrine citrate 100 mg tablets. Indications: NORFLEX is indicated for the relief of stiffness and pain resulting from skeletal muscle spasm in sprains and strains, local muscle injury, prolapsed intervertebral disc, lumbago, fibrositis, non-articular rheumatism, acute torticollis, surgery, fractures, anxiety and tension. Orphenadrine citrate has also been shown to be effective for treatment of tension headache and persistent hiccoughs. Contraindications: Hypersensititvity to orphenadrine, glaucoma, paralytic ileus, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the prostate or bladder neck, oesophageal spasm (megaesophagus) and myasthenia gravis. Warnings and Precautions: Hepatic, renal impairment, tachycardia, cardiac decompensation, coronary insufficiency or cardiac arrhythmias, glaucoma risk. Safety of continuous long-term therapy with orphenadrine has not been established. Therefore periodic monitoring of blood, urine and liver function values is recommended if orphenadrine is prescribed for prolonged use. Pregnancy and lactation: Category B2. Safe use of orphenadrine has not been established with respect to adverse effects on foetal development. NORFLEX should therefore be used in women of childbearing potential and particularly during early pregnancy only when the potential benefits outweigh the risks. Orphenadrine is excreted in breast milk and is not recommended for use while breastfeeding. Effects on ability to drive and operate machinery: NORFLEX may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. Elderly patients: The elderly may be more susceptible to anticholinergic side effects and should be given a reduced dosage. Adverse Effects: common: dryness of mouth, tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Less common: transient episodes of light-headedness, dizziness or syncope. Infrequently, mental confusion in the elderly. These adverse reactions can usually be eliminated by reduction in dosage. Serious or life threatening reactions: Very rare cases of aplastic anaemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established. Interactions: Confusion, anxiety and tremors have been reported in some patients receiving dextropropoxyphene or dextropropoxyphene combinations and orphenadrine concomitantly. Interactions have also been reported with phenothiazines and other drugs with anti-muscarinic properties. Avoid concomitant use of alcohol or other CNS depressants. Dosage and Administration: Adults -NORFLEX tablets: Two tablets per day; one in the morning and one in the evening. Children: not recommended for children under 12 years.

Pharmacy Only Medicine. Pevaryl contains Econazole nitrate 1% w/w. For external use only. Avoid contact with eyes and mucous membranes. May cause a burning sensation and pruritis. Always read the label. Use only as directed. For more information on Pevaryl, refer to the data sheet on www.medsafe.govt.nz.

Qvar Inhaler and Qvar Autohaler are Prescription Medicines containing 50 mcg and 100 mcg of beclomethasone dipropionate per inhalation. Please refer to the data sheet available at www.medsafe.govt.nz before prescribing. Indications: Prophylactic anti-inflammatory treatment of reversible obstructive airways disease including asthma. Contraindications: Hypersensitivity to beclomethasone dipropionate or any other ingredient in Qvar. Not for use in children under 5 years. Precautions: Not for relief of acute attack, pregnancy and lactation. Adverse Effects: Candidiasis of mouth and throat, hoarseness, throat irritation. Qvar Inhalers contain Ethanol and the CFC-free propellant Norflurane (HFA134a). Interactions: No clinically significant drug interactions have been associated with therapeutic doses of BDP. Dose: The recommended total daily dose of Qvar is lower than that for current CFC-BDP products and should be adjusted to the individual patient. Starting and Maintenance Dose: Adults: For mild to moderate asthma: 50 mcg to 200 mcg twice daily. For more severe asthma: doses up to 400 mcg twice daily. Maximum recommended daily dose: 800 mcg. Children: 5 years and over 50 mcg twice daily. In more severe cases this may be increased up to 100 mcg twice daily. Maximum recommended daily dose is 200 mcg. To minimise the systemic effects of orally inhaled steroids, the dose should be titrated down to the lowest that provides effective asthma control. Qvar is a fully funded Prescription Medicine.

RETRIEVE® (Tretinoin 0.05 % w/w). Prescription Medicine.  Indications: Adjunctive treatment of photoaged skin and related conditions. Contraindications: Pregnancy, or women planning a pregnancy. Hypersensitivity to tretinoin or any of the ingredients in the formulation. Precautions: Concomitant application of other topical preparations including cosmetics and medicated cleansers should be avoided, as they may interact with tretinoin, or have a strong drying effect. Effects of keratolytic agents must subside before commencing RETRIEVE®. Minimise exposure to UV irradiation, artificial sunlamps should be avoided during treatment. Patients should routinely use a high SPF sunscreen and protective clothing, and not use RETRIEVE® when sunburnt. Do not apply to eyes, mouth, lips or angles of the nose. Avoid contact with mucous membranes or open wounds. May cause severe irritation on eczematous skin. Interactions: Keratolytic agents such as salicylic acid and other topical preparations. Known photosensitisers (e.g. tetracyclines, sulfonamides). Adverse Effects: Mild irritation, peeling, erythema and slight stinging. Temporary hyperpigmentation or hypopigmentation. Increased sensitivity to UV light. Dosage and Administration: Apply sparingly to the affected areas once daily at bedtime. On first night apply for 5 minutes before washing off, on second night for 10 minutes then wash off, then increase the treatment time each night by 30 minutes for nights three to six until the application is left on for two hours. If no irritation occurs, may be left overnight and washed off next morning. If excessive reaction occurs alternate nights until the skin accommodates. If excessive reactions occur, discontinue temporarily until reactions subside. RETRIEVE, refer to the data sheet on www.medsafe.govt.nz.